JBH-492

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameJBH-492

Drug Alias NameJBH-492

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionC-C chemokine receptor type 7 modulatorsTubulin inhibitors

TargetsC-C chemokine receptor type 7Tubulin

Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingaporeGermanyIsrael +[7]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovartis Pharma Ag

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A